期刊
NEURO-ONCOLOGY
卷 17, 期 2, 页码 180-188出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou154
关键词
adaptive randomization; biomarkers; clinical trials; glioblastoma
资金
- Pfizer
- Novartis
- Genentech
- Basilea
- Sanofi
- Merck
- EMD Serono
Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据